Racotumomab not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Neuroblastoma
- Main trialPhase 2
- “This clinical trial will be carried out in children diagnosed with high-risk neuroblastoma that have achieved a complete or very good partial response after standard therapy. An additional cohort of children who could not achieve these response criteria or that relapsed after standard therapy but do not have progressive disease will receive Racotumomab together with metronomic chemotherapy. The main objectives of this study are to determine the immune response after one-year duration immunization with Racotumomab, to describe the response of Racotumomab therapy in minimal residual disease…”In the company’s words, NCT02998983 on ClinicalTrials.gov
Other drugs for Neuroblastoma
- EB-DTNB-NKBeijing Biotech · Phase 1/2
- APG-115Ascentage Pharma Group Inc. · Phase 1/2
- LisaftoclaxAscentage Pharma Group Inc. · Phase 1/2
- EntrectinibRoche · Phase 1/2
- Zilovertamab vedotinMerck & Co. · Phase 1/2
- Allogenic NK cellsMarzieh Ebrahimi · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Nov 2022 | Racotumomab in Patients With High-risk Neuroblastoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026